Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Posts Higher Q1 Revenues, Enters Black After Aclara Lawsuit Resolved

NEW YORK, April 30 – Caliper Technologies of Mountain View, Calif., said Monday its first-quarter revenues surged as a result of increased licensing fees and product sales.

The company, which makes lab-on-a-chip technology, said its first quarter revenues increased to $9.8 million, compared with $3.9 million a year ago. Caliper attributed $5 million of the increase to fees garnered from licensing patents to Aclara Biosciences.The remaining increase stemmed from a commercial collaboration with Agilent Technologies.

"In this quarter, licensing revenue increased as a component of our overall revenue, consistent with our strategy to expand our revenue sources,” Jim Knighton, Caliper’s chief financial officer, said in a statement.

“Revenue from technology access program customers in the form of licensing and subscription fees and chip and instrument purchases, as well as product sales of the Agilent 2100 Bioanalyzer and R&D funding from Agilent were the other major revenue contributors,” he said.

The company said that sales in the US, Europe, and Japan grew. In addition, Agilent has recently initiated a sales effort in China, Taiwan, Korea and Australia, which are expected to help boost Caliper’s sales.

Increased research and development activity drove operating expenses up $2.5 million to $13.8 million in the first quarter of the year.

For the quarter, Caliper posted net income of $26.4 million, or $1.03 a diluted share, including one-time gains, compared with net losses of $8.3 million, or 40 cents a diluted share, in the year ago period. 

In the first quarter, the company posted $27.5 million, or $1.07 a diluted share, for the dismissal of all suits and countersuits with Aclara. Not including these gains, Caliper would have posted net losses of $1.1 million, or five cents a diluted share. 

The company had $184.2 million at the end of the quarter in cash and investments. The company also posted $32.5 million in other assets, reflecting the guaranteed value of the shares of Aclara’s stock Caliper received as part of a settlement from a legal dispute.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.